Business Context and Reporting Period
This Form 8-K was filed by AlloVir, Inc. (not Kalaris Therapeutics, Inc.) on June 21, 2023. The registrant is a Delaware corporation with its principal executive offices in Waltham, Massachusetts. The filing reports the entry into a material definitive agreement regarding an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 20,000,000 shares of common stock.
- Offering Price: $3.75 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 3,000,000 shares.
- Estimated Net Proceeds: Approximately $70.2 million (base offering) or $80.7 million (if over-allotment is fully exercised), after deducting underwriting discounts, commissions, and estimated offering expenses.
- Underwriters: J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, and BoFA Securities, Inc.
- Expected Closing Date: On or about June 26, 2023.
Material Changes and Lock-Up Provisions
The filing discloses a significant capital raise event. Subject to certain exceptions, AlloVir and its executive officers and directors have agreed to a 90-day lock-up period following the date of the underwriting agreement, during which they will not offer, sell, transfer, or otherwise dispose of any shares of common stock.
Guidance, Outlook, and Risks
The filing does not provide specific operational guidance, revenue forecasts, or management commentary on future business performance beyond the capital raise. The transaction is subject to customary closing conditions. The underwriting agreement includes customary representations, warranties, covenants, and indemnification obligations.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received upon settlement of the offering.
- Confirm whether the underwriters exercised the 3,000,000 share over-allotment option.
- Review the final prospectus supplement filed on June 22, 2023, for detailed use of proceeds.
- Monitor the 90-day lock-up expiration date for potential increases in share supply.